CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial

This 5 year follow up found this dual-drug liposomal encapsulation formulation of daunorubicin and cytarabine maintained better improved overall survival vs 7+3 (non-liposomal) (18% vs 8%, respectively). This supports the previous evidence found from the trial.

The Lancet Haematology